Overview on the treatment of severe bronchial asthma
Childhood asthma, often linked with atopic conditions, poses a challenge when classified as severe and uncontrolled. The 2023 GINA guidelines define severe asthma in children as asthma that remains uncontrolled despite optimized treatment with high-dose ICS-LABA or requires high-dose ICS-LABA to pre...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | Global Pediatrics |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667009723000830 |
| _version_ | 1827317834891395072 |
|---|---|
| author | Giulio Dinardo Cristiana Indolfi Angela Klain Chiara Lucia Bencivenga Serena Ferrara Fabio Decimo Michele Miraglia del Giudice |
| author_facet | Giulio Dinardo Cristiana Indolfi Angela Klain Chiara Lucia Bencivenga Serena Ferrara Fabio Decimo Michele Miraglia del Giudice |
| author_sort | Giulio Dinardo |
| collection | DOAJ |
| description | Childhood asthma, often linked with atopic conditions, poses a challenge when classified as severe and uncontrolled. The 2023 GINA guidelines define severe asthma in children as asthma that remains uncontrolled despite optimized treatment with high-dose ICS-LABA or requires high-dose ICS-LABA to prevent it from becoming uncontrolled. This category encompasses about 5% of pediatric asthma cases, emphasizing the need for innovative therapeutic exploration. Advances in understanding asthma phenotypes and endotypes enable personalized treatment based on biomarkers. Monoclonal antibodies offer targeted solutions, reducing exacerbations, improving lung function, and minimizing corticosteroid use in pediatric patients. Integrating these therapies requires a personalized approach by healthcare providers, enhancing outcomes in severe and refractory cases. |
| first_indexed | 2024-03-08T17:22:40Z |
| format | Article |
| id | doaj.art-5d948ff586e04fa68077415e1b7a4f9c |
| institution | Directory Open Access Journal |
| issn | 2667-0097 |
| language | English |
| last_indexed | 2024-04-24T23:46:31Z |
| publishDate | 2024-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Global Pediatrics |
| spelling | doaj.art-5d948ff586e04fa68077415e1b7a4f9c2024-03-15T04:44:52ZengElsevierGlobal Pediatrics2667-00972024-03-017100117Overview on the treatment of severe bronchial asthmaGiulio Dinardo0Cristiana Indolfi1Angela Klain2Chiara Lucia Bencivenga3Serena Ferrara4Fabio Decimo5Michele Miraglia del Giudice6Department of Woman, Child and General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples, ItalyCorresponding author at: Cristiana Indolfi Department of Woman, Child and General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples, Italy.; Department of Woman, Child and General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples, ItalyDepartment of Woman, Child and General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples, ItalyDepartment of Woman, Child and General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples, ItalyDepartment of Woman, Child and General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples, ItalyDepartment of Woman, Child and General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples, ItalyDepartment of Woman, Child and General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples, ItalyChildhood asthma, often linked with atopic conditions, poses a challenge when classified as severe and uncontrolled. The 2023 GINA guidelines define severe asthma in children as asthma that remains uncontrolled despite optimized treatment with high-dose ICS-LABA or requires high-dose ICS-LABA to prevent it from becoming uncontrolled. This category encompasses about 5% of pediatric asthma cases, emphasizing the need for innovative therapeutic exploration. Advances in understanding asthma phenotypes and endotypes enable personalized treatment based on biomarkers. Monoclonal antibodies offer targeted solutions, reducing exacerbations, improving lung function, and minimizing corticosteroid use in pediatric patients. Integrating these therapies requires a personalized approach by healthcare providers, enhancing outcomes in severe and refractory cases.http://www.sciencedirect.com/science/article/pii/S2667009723000830AsthmaSevere asthmaChildrenPrecision medicineMonoclonal antibodiesBiologics |
| spellingShingle | Giulio Dinardo Cristiana Indolfi Angela Klain Chiara Lucia Bencivenga Serena Ferrara Fabio Decimo Michele Miraglia del Giudice Overview on the treatment of severe bronchial asthma Global Pediatrics Asthma Severe asthma Children Precision medicine Monoclonal antibodies Biologics |
| title | Overview on the treatment of severe bronchial asthma |
| title_full | Overview on the treatment of severe bronchial asthma |
| title_fullStr | Overview on the treatment of severe bronchial asthma |
| title_full_unstemmed | Overview on the treatment of severe bronchial asthma |
| title_short | Overview on the treatment of severe bronchial asthma |
| title_sort | overview on the treatment of severe bronchial asthma |
| topic | Asthma Severe asthma Children Precision medicine Monoclonal antibodies Biologics |
| url | http://www.sciencedirect.com/science/article/pii/S2667009723000830 |
| work_keys_str_mv | AT giuliodinardo overviewonthetreatmentofseverebronchialasthma AT cristianaindolfi overviewonthetreatmentofseverebronchialasthma AT angelaklain overviewonthetreatmentofseverebronchialasthma AT chiaraluciabencivenga overviewonthetreatmentofseverebronchialasthma AT serenaferrara overviewonthetreatmentofseverebronchialasthma AT fabiodecimo overviewonthetreatmentofseverebronchialasthma AT michelemiragliadelgiudice overviewonthetreatmentofseverebronchialasthma |